RLAY
Relay Therapeutics, Inc.
$19.63
-0.11 (-0.56%)
At close · Jul 8
Market Cap
$3.98B
Shares
191,586,165
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.63
Open$19.71
Day$18.37–20.19
52W$3.03–20.20
Avg vol 30d3.8M
Short int38.1M · 19.9% float · 9.9d
Short vol47%
Last earningsMay 5, 2026
DataJul 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+93%
above
Price vs 50-day avg
+32%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
97%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+44%
trailing
6-month return
+147%
trailing
YTD return
+132%
this year
Relative strength
+140%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
5 of 242 funds reported for Jun 30 · net +2.4K sh shares
Insider flow
Distributing
Net -$275.4K over 90 days · 100% sells
Short interest
Rising
19.90% of float · ▲ +10.9% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
242 holders — near 3-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
+53%
Y/Y
EPS growth
+32%
Y/Y
Free cash flow
$-235.9M
Balance sheet
$84.0M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 23, 2027
Est · unconfirmed
· in 59 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+93%
Bullish
Price vs 50-day avg
+32%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
97%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $15 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
5 of 242 funds reported for Jun 30 · net +2.4K sh shares
Insider flow
Distributing
Net -$275.4K over 90 days · 100% sells
Short interest
Rising
19.90% of float · ▲ +10.9% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
242 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $20 · 97%
52-wk high $20
vs 200-day avg +93%
vs 50-day avg +32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RLAY
this stock
Relay Therapeutics, Inc.
|
$3.98B | +132.0% | +53.4% | — | 19.9% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RLAY | +4.9% | +43.7% | +147.2% | +4.9% | +132.0% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +5.1% | +42.9% | +139.8% | +5.1% | +122.7% |